title: Reply.
authors.affiliation: The Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
authors.forename: Raafay
authors.initials: R
authors.lastname: Sophie
authors.affiliation: Genentech Inc, South San Francisco, California.
authors.forename: Na
authors.initials: N
authors.lastname: Lu
authors.affiliation: The Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. Electronic address: pcampo@jhmi.edu.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Campochiaro
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D005584:Fovea Centralis / Q000473:pathology*; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D014792:Visual Acuity / Q000502:physiology*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized